Adding lomustine to standard care for MGMT‑methylated glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized Phase 3 trial that compares standard treatment (temozolomide during and after radiation) to the same regimen with lomustine added. Eligible participants are adults 18–70 with newly diagnosed IDH‑wildtype glioblastoma and a methylated MGMT promoter and a WHO performance status of 0–2. Patients are randomly assigned to one of the two treatment arms and followed for survival, safety, and quality‑of‑life outcomes. The trial builds on prior randomized data suggesting potential benefit from combining lomustine with temozolomide in this molecular subgroup.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed glioblastoma/gliosarcoma, IDH wild type
* Methylated MGMT promoter
* World Health Organization performance status 0-2
* Age 18-70

Exclusion Criteria:

* Previous malignancy within 3 y or malignancy treated non-curatively
* Previous chemotherapy or radiotherapy involving the head
* Off-protocol tumor-specific treatment
* Serious comorbidity

Where it's running

• Kepler University Hospital
  Linz, Austria Recruiting
• Aarhus University Hospital
  Aarhus, Denmark Recruiting
• Haukeland University Hospital
  Bergen, Norway Recruiting
• Sorlandet Sykehus
  Kristiansand, Norway Recruiting
• Oslo University Hospital
  Oslo, Norway Recruiting
• Gävle Hospital
  Gävle, Sweden Recruiting

Study contacts

• Principal investigator: Annika Malmström, MD, PhD — University Hospital, Linkoeping
• Study coordinator: Asgeir S Jakola, MD, PhD
• Email: asgeir.jakola@vgregion.se
• Phone: +46313429741

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Temozolomide with or without WSD0922-FU for EGFR-Mutant, IDH-Wildtype Glioblastoma

  This trial tests whether adding WSD0922-FU to temozolomide helps slow disease progression in adults with EGFR-mutant, IDH-wildtype glioblastoma.

  Recruiting at 3 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT07708961

• Retifanlimab With or Without DFMO for Progressive High-Grade Gliomas

  This trial tests whether retifanlimab, with or without DFMO, is safe and may help treat progressive high-grade gliomas in adults.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT07468136

• Temporally-Modulated Pulsed Radiation Therapy plus TMZ for MGMT-Unmethylated Glioblastoma

  This study tests whether temporally-modulated pulsed radiation therapy plus temozolomide improves outcomes for people with newly diagnosed MGMT-unmethylated, IDH-wildtype glioblastoma.

  Recruiting at 54 sites Phase 3 NRG Oncology · Irvine, California and 53 other locations · NCT07452458

• GI-102 With or Without Pembrolizumab Before Surgery for Recurrent or Progressive Grade 4 Gliomas

  The team will test whether giving GI-102 alone or together with pembrolizumab before surgery helps adults with recurrent or progressive IDH‑wildtype glioblastoma or IDH‑mutant grade 4 astrocytoma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07301268

• 177Lu-PSMA-617 treatment for IDH‑wildtype gliomas

  This trial will test whether the radiopharmaceutical 177Lu-PSMA-617 is safe for adults with IDH‑wildtype gliomas who have completed standard surgery and radiation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07223034

• Using a continuous glucose monitor to manage high blood sugar in glioblastoma

  We will try continuous glucose monitors to help adults with newly diagnosed glioblastoma control high blood sugar during treatment.

  Recruiting Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT07091864

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.